Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus COXANTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus COXANTO.
ADVIL LIQUI-GELS vs COXANTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
1 g intravenous every 6 hours.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
NSAID
NSAID